GRAIL (GRAL) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue reached $31.8 million, up 19% year-over-year, driven by a 31% increase in Galleri test volume and significant progress in clinical and commercial milestones.

• Net loss improved by 51% to $106.2 million, reflecting lower R&D, sales, and G&A expenses after restructuring.

• Over 37,000 Galleri tests sold in Q1; cumulative sales exceed 325,000 since launch.

• Announced positive top-line results from the NHS-Galleri trial's first screening round, showing higher positive predictive value than prior studies.

• Completed spin-off from Illumina in June 2024, becoming an independent public entity.

Financial highlights

• Screening revenue was $29.1 million, up 24% year-over-year; development services revenue was $2.7 million, down 15%.

• Adjusted gross profit was $14.3 million, up 19% year-over-year.

• Adjusted EBITDA improved to $(98.7) million from $(152.0) million year-over-year.

• Net loss per share was $(3.10), compared to $(7.05) in Q1 2024.

• Cash, cash equivalents, and short-term marketable securities totaled $677.9 million at quarter end, with projected 2025 cash burn capped at $320 million.

Outlook and guidance

• Final NHS-Galleri trial results and FDA premarket approval submission targeted for first half of 2026; PATHFINDER 2 data to be shared in late 2025.

• Cash runway extends into 2028, supporting achievement of major clinical and regulatory milestones.

• Management expects continued operating losses as investments in R&D and commercialization persist.

• R&D expenses expected to decrease over the next three years as large clinical trials conclude.

• Commercial growth in 2025 expected from TRICARE coverage, Quest Diagnostics integration, and international expansion.